case_images: PMC7280536_01
case_images: Chest CT shows multiple lung cancers. (A) Adenocarcinoma, (B) pleomorphic carcinoma, (C) adenocarcinoma, (D) positron emission tomography computed tomography (PET-CT) of pleomorphic carcinoma (B), (E) PET-CT of adenocarcinoma (C).
case_images: fonc-10-00689-g0001.jpg
case_images: PMC7280536_01_fonc-10-00689-g0001.jpg
case_images: F1
case_images: A CT scan showed that an 87-year-old man had three nodules in his right upper lobe of the lung (Figure 1).
case_images: Relationship between pathology and somatic mutations.
case_images: fonc-10-00689-g0002.jpg
case_images: PMC7280536_01_fonc-10-00689-g0002.jpg
case_images: F2
case_images: Also, OncoScan CNV (Affymetrix) Thermo Fisher Scientific, Tokyo, Japan was performed to analyze chromosomal aberrations (Figures 2, 3). A pleomorphic carcinoma had a uniform carcinoma which cancer cells had occupied more than 80% of the central tumor area (Figure 2).
case_images: Structural chromosome aberration analysis by OncoScan CNV. Common chromosomal aberrations were found in chromosomes 8 and 10, and the process that piled up independent chromosomal aberrations was inquired of these tumors having a common origin.
case_images: fonc-10-00689-g0003.jpg
case_images: PMC7280536_01_fonc-10-00689-g0003.jpg
case_images: F3
case_images: Also, OncoScan CNV (Affymetrix) Thermo Fisher Scientific, Tokyo, Japan was performed to analyze chromosomal aberrations (Figures 2, 3). Structural chromosome aberration analysis by DNA microarray showed great difference between two tumors, but also common chromosomal aberration in chromosomes 8 and 10 and partially common chromosomal aberration in chromosomes 4, 14, 17, and X (Figure 3).
case_images: Response evaluation was shown as PR after intravenous injection of immune checkpoint inhibitors.
case_images: fonc-10-00689-g0004.jpg
case_images: PMC7280536_01_fonc-10-00689-g0004.jpg
case_images: F4
case_images: One month after pembrolizumab injection, multiple metastatic pulmonary and liver tumors were reduced in size and judged as PR (Figure 4). Overall response evaluation of immune checkpoint inhibitors at 12 months after the treatment was judged as PR (Figure 4).